|
An Ethical Template For Pharmacy Benefits
Norman Daniels,
J. Russell Teagarden and
James E. Sabin
We propose an ethical template for pharmacy benefits and a fair process for using it. The template delineates four levels of decisions about pharmacy coverage, connecting ethically acceptable types of rationales for limits with decisions made at each level. It provides a framework for organizing ethically relevant reasons for coverage (or the tiered copayments). The process for using the template assures accountability for the reasonableness of benefit decisions. It requires transparency and relevance of rationales for limit setting and revisability of decisions, including through fair procedures for appeals. The template and the process facilitate broader public learning about fair limit setting.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
G. P. Browman, B. Manns, N. Hagen, C. R. Chambers, A. Simon, and S. Sinclair
6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs
J. Oncol. Pract,
January 1, 2008;
4(1):
2 - 7.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Calfee
Can Quality-Adjusted Life Year Avoidance Help in Oncology Drug Reimbursement Decisions?
J. Oncol. Pract,
January 1, 2008;
4(1):
8 - 8.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Teagarden and M. K. Wynia
Ensuring fairness in coverage decisions: Applying the American Medical Association Ethical Force Program's consensus report to managed care pharmacy.
Am. J. Health Syst. Pharm.,
September 15, 2006;
63(18):
1749 - 1754.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Morgan, M. McMahon, C. Mitton, E. Roughead, R. Kirk, P. Kanavos, and D. Menon
Centralized drug review processes in australia, Canada, new zealand, and the United kingdom.
Health Aff.,
March 1, 2006;
25(2):
337 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Daniels and J. Sabin
Comment
Clinical Trials,
February 1, 2004;
1(1):
116 - 117.
[PDF]
|
|
|
|
